Publications by Jun Ishihara | EPFL Graph Search

Targeted antibody and cytokine cancer immunotherapies through collagen affinity

Jeffrey Alan Hubbell, Melody Swartz, Seung Tae Lee, Lambert Charles François Potin, Jun Ishihara, Kazuto Fukunaga, Michal Mateusz Raczy

Cancer immunotherapy with immune checkpoint inhibitors (CPIs) and interleukin-2 (IL-2) has demonstrated clinical efficacy but is frequently accompanied with severe adverse events caused by excessive and systemic immune system activation. Here, we addressed ...

AMER ASSOC ADVANCEMENT SCIENCE2019

The heparin binding domain of von Willebrand factor binds to growth factors and promotes angiogenesis in wound healing

Matthias Lütolf, Jeffrey Alan Hubbell, Yoji Tabata, Jun Ishihara, Kazuto Fukunaga

During wound healing, the distribution, availability, and signaling of growth factors (GFs) are orchestrated by their binding to extracellular matrix components in the wound microenvironment. Extracellular matrix proteins have been shown to modulate angiog ...

AMER SOC HEMATOLOGY2019

Recruitment of CD103(+) dendritic cells via tumor-targeted chemokine delivery enhances efficacy of checkpoint inhibitor immunotherapy

Jeffrey Alan Hubbell, Melody Swartz, Lambert Charles François Potin, Jun Ishihara

Although a clinical breakthrough for cancer treatment, it remains that a minority of patients respond to checkpoint inhibitor (CPI) immunotherapy. The composition of tumor-infiltrating immune cells has been identified as a key factor influencing CPI therap ...

2019

Improving Efficacy and Safety of Agonistic Anti-CD40 Antibody Through Extracellular Matrix Affinity

Jeffrey Alan Hubbell, Melody Swartz, Lambert Charles François Potin, Martina Damo, Jun Ishihara, Kazuto Fukunaga

CD40 is an immune costimulatory receptor expressed by antigen-presenting cells. Agonistic anti-CD40 antibodies have demonstrated considerable antitumor effects yet can also elicit serious treatment-related adverse events, such as liver toxicity, including ...

AMER ASSOC CANCER RESEARCH2018

Matrix-binding checkpoint immunotherapies enhance antitumor efficacy and reduce adverse events

Jeffrey Alan Hubbell, Melody Swartz, Lambert Charles François Potin, Hans Mattias Larsson, Gabriele Galliverti, Jun Ishihara, Kazuto Fukunaga

Immune checkpoint blockade exhibits considerable antitumor activity, but previous studies have reported instances of severe treatment-related adverse events. We sought to explore local immune checkpoint blockade, with an antibody (Ab) form that would be re ...

Amer Assoc Advancement Science2017